Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with 2'-deoxycoformycin

D Catovsky1

  • 1Academic Department of Haematology, Royal Marsden Hospital, London, England.

Hematology and Cell Therapy
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.

Nature genetics·1997
Same author

The human T-cell lymphotropic viruses types I/II are not involved in T prolymphocytic leukemia and large granular lymphocytic leukemia.

Leukemia·1997
Same author

The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study.

British journal of haematology·1997
Same author

G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaemia.

Bone marrow transplantation·1997
Same author

Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?

Leukemia·1997
Same author

Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1997
Same journal

The place of instruments in the scientific work of Marcel Bessis (1917-1994): the electron microscope and the ektacytometer.

Hematology and cell therapy·2001
Same journal

In memory of Marcel Bessis.

Hematology and cell therapy·2001
Same journal

Emerging therapies and future directions in CLL--monoclonal antibodies, vaccines and gene therapy.

Hematology and cell therapy·2000
Same journal

Emerging therapies and future directions in chronic lymphocytic leukaemia--chemotherapy.

Hematology and cell therapy·2000
Same journal

Chronic lymphocytic leukemia . Clinical oral poster session.

Hematology and cell therapy·2000
Same journal

Current therapy for CLL.

Hematology and cell therapy·2000
See all related articles

2'-deoxycoformycin (DCF) demonstrates significant efficacy in treating lymphoproliferative disorders, particularly hairy cell leukemia (HCL). Long-term remission rates in HCL patients treated with DCF are very encouraging, supporting its role in treatment strategies.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • 2 -deoxycoformycin (DCF) is a long-established nucleoside analog used in treating lymphoproliferative disorders.
  • Its efficacy has been particularly noted in B and T cell malignancies.

Purpose of the Study:

  • To evaluate the long-term efficacy and remission rates of 2 -deoxycoformycin (DCF) in patients with hairy cell leukemia (HCL).
  • To review the activity of DCF in other lymphoid malignancies, including chronic lymphocytic leukemia and T-cell lymphomas.

Main Methods:

  • A large, ten-year, phase II study involving 165 evaluable hairy cell leukemia (HCL) patients treated with DCF (4mg/m2 every 2 weeks).
  • Review of existing data on DCF activity in chronic lymphocytic leukemia, T-prolymphocytic leukemia (T-PLL), and Sezary syndrome.

Related Experiment Videos

Main Results:

  • DCF treatment resulted in a very long disease-free interval in HCL patients.
  • 76% of complete responders in the HCL study remained in remission at 6 years.
  • DCF showed activity in T-prolymphocytic leukemia (T-PLL) and Sezary syndrome, with good outcomes when combined with CAMPATH-1H in T-PLL.

Conclusions:

  • 2 -deoxycoformycin (DCF) is highly effective in achieving long-term remission in hairy cell leukemia (HCL).
  • DCF should be considered a valuable component of treatment strategies for various B and T lymphoproliferative disorders.
  • Further investigation into DCF regimens, such as low-dose five-day protocols, is warranted for other leukemias.